FIELD: medicine.
SUBSTANCE: method involves introducing to a mammal therapeutic dose of drug having at least one subunit or at least one oligomer of mannan-binding lectin comprising one mannan-binding lectin subunit.
EFFECT: reduced risk of infection development; enhanced effectiveness in acting upon agents resistant to usual therapy.
43 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN RECOMBINANT MANNAN-BINDING LECTIN | 2000 |
|
RU2292217C2 |
| METHOD FOR DETERMINING ACTIVITY OF MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASES IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2739113C1 |
| DETERMINING THE ACTIVITY OF THE CLASSICAL PATHWAY OF THE COMPLEMENT SYSTEM IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2707568C1 |
| METHOD FOR ESTIMATION OF HUMAN BODY IMMUNE SYSTEM | 2006 |
|
RU2314529C1 |
| POLYSACCHARIDE AND ITS DERIVATIVES WITH ACTIVITY TO FICOLIN-3, METHOD FOR OBTAINING AND APPLICATION THEREOF | 2011 |
|
RU2575752C2 |
| METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2662563C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2718850C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2830289C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2743409C2 |
| METHOD FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2010 |
|
RU2600876C2 |
